Key Takeaways:
- Located in Strasbourg, France, Dianosic is a startup specializing in innovative solutions for Ear, Nose, and Throat (ENT) conditions. This startup operates at the intersection of Medtech and Biotech with a strong focus on drug-device combinations.
- Dianosic’s strategic aim is to establish new treatment paradigms within Chronic Rhinitis and Chronic Sinusitis by utilizing its Active Resorbable Scaffold (ARIS) which is a drug-device combination developed together with world-renowned resorbable polymers experts.
- The startup also tackles intranasal bleeding, a widespread condition in ENT, by commercializing an Asymmetric Intranasal inflatable solution (CAVI-T) for its treatment. CAVI-T has demonstrated the company’s ability not only to develop differentiated technology but also to successfully transition from R&D to Sales.
- Dianosic aims to capitalize on opportunities to create other verticals, especially in the field of chronic migraine and facial pain.
- Present in the relevant markets in the EU, Dianosic is planning to expand into the US market in the mid-term.
As the healthcare industry continues to evolve, fusions between different scientific areas are becoming increasingly prevalent. One startup which symbolizes this trend is Strasbourg-based Dianosic. Founded in 2017, Dianosic works at the intersection of MedTech and BioTech, developing innovative solutions for Ear, Nose, and Throat (ENT) conditions. Dianosic operates in a market valued at $50 billion dollars, demonstrating double-digit growth in a sector that is still largely underserviced, presenting a huge opportunity for innovative startups.
Dianosic’s philosophy is centered around identifying and addressing unmet clinical needs. Stemming from the University Hospital of Strasbourg’s ENT Department, the startup has a distinct focus on Chronic Rhinitis, Chronic Sinusitis, and intranasal bleeding (Epistaxis). It is setting a pace with its unique approach of combining medical and bio-technologies to provide better solutions for these conditions.
Dianosic differentiates itself through its innovative solutions, particularly its Active Resorbable Scaffold (ARIS). ARIS is a drug-device combination that has the potential to establish a new paradigm in treating Chronic Rhinitis and Chronic Sinusitis. Moreover, Dianosic’s groundbreaking work does not stop with ARIS. It has also developed an Asymmetric Intranasal inflatable solution (CAVI-T) for the treatment of intranasal bleeding. This technology, which is already CE-marked and FDA registered, addresses a clear yet highly prevalent unmet need within the ENT field.
The startup also has a vision of expanding the application of its ARIS platform into areas such as chronic migraine and facial pain treatment, further highlighting its innovative approach and potential for growth. Moreover, it has successfully transitioned from R&D to sales, demonstrating its operational competency and potential for market dominance.
Looking to the future, Dianosic’s innovative solutions and strategic vision put it in a strong position for sustainable growth. The fusion of Medtech and Biotech holds enormous promise for the treatment of Chronic ENT conditions, and Dianosic is at the forefront of this exciting development. Furthermore, with plans to expand its presence to the US market, the growth trajectory for Dianosic has exciting potential.
Undoubtedly, Dianosic’s strategic goal of establishing new standards of care levering the combination of Medtech and Biotech could be game-changing for Chronic ENT Condition Treatment. Interested readers can learn more about Dianosic and follow their progress on their website, their Twitter, and LinkedIn pages.
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
